About us

AnaMar AB is a pharmaceutical company that specializes in the development of 5-HT2B receptor antagonists for various types of fibrotic diseases.

Our project portfolio includes the candidate drug AM1476, which is currently in planning of a Phase II clinical study. In addition, we have a portfolio of additional patented highly selective, orally bioavailable, peripherally-acting 5-HT2B receptor antagonists.

AnaMar AB is a privately held company.

Team

Ulf Ljungberg

PhD, CEO

Dr. Ljungberg joined AnaMar in 2015. He has long experience from Life science in executive management, licensing/business development and marketing/sales positions in various countries in big pharma and as CEO of biotech start-ups.

Sam Lindgren

MD, PhD, MBA, CMO

Dr. Lindgren joined AnaMar as Chief Medical Officer in 2021. He brings more than 25 years of big pharma experience of clinical drug development, translational medicine, pharmacovigilance, strategy development and senior leadership roles from AstraZeneca, Novartis, Lundbeck and Novo Nordisk.

Denise Goode

BSc, FCA (ICAEW), MIoD, VP BD

Mrs. Goode joined AnaMar in 2015 bringing financial, commercial and industry dealmaking experience. She is a non executive director of Dechra Pharmaceuticals PLC and Abliva AB. Previously, she served in senior leadership positions with AstraZeneca.

Lars Pettersson

PhD, HEAD OF CHEMISTRY & IP

Dr. Pettersson joined AnaMar in 2011 and is responsible for the medicinal chemistry and intellectual property related activities. He has more than 30 years of drug discovery experience, having served in a number of leadership roles at big pharma and biotech companies.

Christina Wenglén

PhD, HEAD OF RESEARCH

Dr. Wenglén joined AnaMar in 2007 and is responsible for the research and pharmacology at AnaMar. She has a PhD in Medical Science and has previously conducted research at Lund University, focusing on extracellular matrix biology and rheumatic diseases.

Helena Arozenius

MSc, HEAD OF DRUG DEVELOPMENT

Ms. Arozenius joined AnaMar in 2005 and is responsible for the development activities. She has substantial experience in project management in early phase development projects.

Ingegerd Dalfelt

BSc, SENIOR CLINICAL PROJECT MANAGER

Mrs. Dalfelt joined AnaMar in 2019 and is responsible for the CRO oversight. She has over 25 years of experience, including different roles with increasing responsibility, mainly within the CRO industry.

Board of directors

Staffan Encrantz

CHAIRMAN

Mr. Encrantz is the Chairman and CEO of Allegro Investment Inc. and represents the owner of AnaMar. He is a private investor who has led the growth and development of a number of early stage businesses to highly successful realizations.

Marie Encrantz

Ms. Encrantz is an EVP and the CFO of Allegro Investment Inc., the Investment Manager of the owner of AnaMar. She has been working in the Allegro group since 2004 and is mainly responsible for financing, accounting and administration. Before Allegro, she spent 7 years in accounting at a semiconductor manufacturer in Silicon Valley.

Anders Ekblom

MD, PhD, DDS, ASSOCIATE PROFESSOR

Dr. Ekblom has substantial experience from senior positions in the biopharmaceutical industry. He has been the executive vice president of Global Medicines Development at AstraZeneca, and the CEO of AstraZeneca Sweden AB. Currently, he is a board member of a number of life science companies.

Ulf Ljungberg

PhD, CEO

Dr. Ljungberg joined AnaMar in 2015. He has long experience from Life science in executive management, licensing/business development and marketing/sales positions in various countries in big pharma and as CEO of biotech start-ups.